Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next Generation Chemiluminescent Probes for Antimalarial Drug Discovery.
Hellingman A, Sifoniou K, Buser T, Thommen BT, Walz A, Passecker A, Collins J, Hupfeld M, Wittlin S, Witmer K, Brancucci NMB. Hellingman A, et al. Among authors: collins j. ACS Infect Dis. 2024 Apr 12;10(4):1286-1297. doi: 10.1021/acsinfecdis.3c00707. Epub 2024 Apr 1. ACS Infect Dis. 2024. PMID: 38556981 Free PMC article.
Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022.
Caldwell N, Afshar R, Baragaña B, Bustinduy AL, Caffrey CR, Collins JJ, Fusco D, Garba A, Gardner M, Gomes M, Hoffmann KF, Hsieh M, Lo NC, McNamara CW, Nono JK, Padalino G, Read KD, Roestenberg M, Spangenberg T, Specht S, Gilbert IH. Caldwell N, et al. Among authors: collins jj. ACS Infect Dis. 2023 May 12;9(5):1046-1055. doi: 10.1021/acsinfecdis.3c00081. Epub 2023 Apr 21. ACS Infect Dis. 2023. PMID: 37083395 Free PMC article. Review.
Factors associated with medical consumable availability in level 1 facilities in Malawi: a secondary analysis of a facility census.
Mohan S, Mangal TD, Colbourn T, Chalkley M, Chimwaza C, Collins JH, Graham MM, Janoušková E, Jewell B, Kadewere G, Li Lin I, Manthalu G, Mfutso-Bengo J, Mnjowe E, Molaro M, Nkhoma D, Revill P, She B, Manning Smith R, Tafesse W, Tamuri AU, Twea P, Phillips AN, Hallett TB. Mohan S, et al. Among authors: collins jh. Lancet Glob Health. 2024 Jun;12(6):e1027-e1037. doi: 10.1016/S2214-109X(24)00095-0. Lancet Glob Health. 2024. PMID: 38762283 Free article.
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: collins j. Nat Commun. 2024 May 10;15(1):3957. doi: 10.1038/s41467-024-48359-1. Nat Commun. 2024. PMID: 38730268 Free PMC article. No abstract available.
7,232 results